Citation Impact
Citing Papers
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
2013 StandoutNobel
Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces Autoimmunity
2006
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma
1997
Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
1995 StandoutNobel
Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma
2013
Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
1997 StandoutNobel
Interleukin‐6: Structure‐function relationships
1997
Lymphocyte responses to stress in postpartum women: relationship to vagal tone
2001
Active immunization against cancer with dendritic cells: The near future
2001 StandoutNobel
Hypomorphic Mutation in the Site-1 Protease Mbtps1 Endows Resistance to Persistent Viral Infection in a Cell-Specific Manner
2011 StandoutNobel
Neuroblastoma: biological insights into a clinical enigma
2003 Standout
Pregnancy Maintenance and Parturition: The Role of Prostaglandin in Manipulating the Immune and Inflammatory Response
1994
IL-6 as a keystone cytokine in health and disease
2015 Standout
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.
1998 Standout
Monoclonal Anti‐P‐glycoprotein Antibody‐dependent Killing of Multidrug‐resistant Tumor Cells by Human Mononuclear Cells
1990
Interleukin-2 toxicity.
1991
Ethanol Decreases Natural Killer Cell Activation but Only Minimally Affects Anatomical Distribution After Administration of Polyinosinic:Polycytidylic Acid: Role in Resistance to B16F10 Melanoma
2003
Acute Stressors and Cortisol Responses: A Theoretical Integration and Synthesis of Laboratory Research.
2004 Standout
Targeting multidrug resistance in cancer
2006 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Testicular germ-cell tumours in a broader perspective
2005 Standout
The impact of T‐cell immunity on ovarian cancer outcomes
2008
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
2011 Standout
Chromosomes, genes, and development of testicular germ cell tumors
2004
Graft-versus-host disease
2009 Standout
Clinical application of IL6 in cancer therapy
1992
Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma
2005
Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells
2011
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
2008 Standout
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
2011 StandoutNobel
MIXED CHIMERISM AS AN APPROACH FOR THE INDUCTION OF TRANSPLANTATION TOLERANCE1
1999
The Janus face of dendritic cells in cancer
2008
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Eicosanoids and cancer
2010 Standout
Strategies to Improve Long-Term Outcomes after Renal Transplantation
2002 Standout
Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors
1994
Tumor microenvironment is multifaceted
2011
Neuroblastoma
2007 Standout
Tumor‐cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small‐cell lung carcinoma
1991
Innate immunity of the newborn: basic mechanisms and clinical correlates
2007 Standout
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
Ectopic lymphoid-like structures in infection, cancer and autoimmunity
2014
Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells
1991
Psychological Stress and the Human Immune System: A Meta-Analytic Study of 30 Years of Inquiry.
2004 Standout
Convergent Mechanisms for Recognition of Divergent Cytokines by the Shared Signaling Receptor gp130
2003 StandoutNobel
Prevention of manifest metastasis with monoclonal antibodies: A novel approach to immunotherapy of solid tumours
1995
Interleukin‐6 and its receptor in cancer
2007
The emerging phenotype of the testicular carcinoma in situ germ cell
2003
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
Dendritic cell infiltration and prognosis of human hepatocellular carcinoma
2006
Passive and active components of neonatal innate immune defenses
2005
Biomimetic Engineering of Carbon Nanotubes by Using Cell Surface Mucin Mimics
2004 StandoutNobel
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines
1997
Hierarchical Assembly of Model Cell Surfaces: Synthesis of Mucin Mimetic Polymers and Their Display on Supported Bilayers
2007 StandoutNobel
Extinction of the tumor necrosis factor locus, and of genes encoding the lipopolysaccharide signaling pathway.
1993 StandoutNobel
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
Cyclooxygenases: Structural, Cellular, and Molecular Biology
2000 Standout
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
2004 StandoutNobel
Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice
1998 Standout
Lectins: Carbohydrate-Specific Proteins That Mediate Cellular Recognition
1998 Standout
Therapeutic Glucocorticoid-Induced TNF Receptor-Mediated Amplification of CD4+ T Cell Responses Enhances Antiparasitic Immunity
2010 StandoutNobel
Production of tumour necrosis factor by mastocytoma P815 cells.
1990
Specific Suppressor T‐Cells Immune to Antigens of the H‐2 Complex: Receptors, Clonal Structure, Genetic Restriction and Antigenic Markers
1984
Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents.
2001
Lectin Receptors as Lymphocyte Surface Markers
1983
The Danger Model: A Renewed Sense of Self
2002 StandoutScience
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
T cell tolerance by clonal elimination in the thymus
1987 Standout
Inhibition of Toll-like Receptor and Cytokine Signaling—A Unifying Theme in Ischemic Tolerance
2004 StandoutNobel
Free radical theory of aging: Beneficial effect of antioxidants on the life span of male NZB mice; role of free radical reactions in the deterioration of the immune system with age and in the pathogenesis of systemic lupus erythematosus
1980
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
2014 StandoutNobel
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-Versus-Host Disease
2004 StandoutNobel
The aging process.
1981 Standout
Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects
2006
Induced pluripotent stem cells: opportunities and challenges
2011 StandoutNobel
Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production.
1998
Therapeutic effects of monoclonal antibody g250, interferons and tumor necrosis factor, in mice with renal‐cell carcinoma xenografts
1994
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
2001
Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients
2004
Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors
2002
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Works of Avi Eisenthal being referenced
Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy
1993
Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer
2001
Decrease of intracellular fluorescein fluorescence polarization (IFFP) in human peripheral blood lymphocytes undergoing stimulation with phytohaemagglutinin (PHA), concanavalin A (ConA), pokeweed mitogen (PWM) and anti‐CD3 antibody
1996
Phenotype and function of lymphocytes from the neonatal umbilical cord compared to paired maternal peripheral blood cells isolated during delivery
2003
Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells
1993
Inhibition of CT-26 Murine Adenocarcinoma Growth in the Rectum of Mice Treated with Recombinant Human Interleukin-6
1994
Characterization of IL-2-induced murine cells which exhibit ADCC activity
1988
Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2
1990
Localization of a specific germ cell marker, DAZL1, in testicular germ cell neoplasias
2001
Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
1988
Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
1988
The in vitro generation of suppressor lymphocytes involves interactions between PNA+ and PNA- thymocyte populations.
1982
Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors
1989
Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
1987
Absence of RBM expression as a marker of intratubular (in situ) germ cell neoplasia of the testis
2000
Induction of allospecific suppressor T Cells in vitro
1977
Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
1990
The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha.
1989
Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
1987
Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.
1988
Studies of Allospecific Suppressor Cells in Culture
1979